All commercially available norepinephrine salt formulations are clinically equivalent. The critical focus for researchers and clinicians must shift from debating the formulation to ensuring clear and standardized reporting of drug doses based on the active norepinephrine molecule.

This clarity is essential for designing future trials, interpreting evidence accurately, and applying research findings safely in patient care.

The true source of confusion and scientific heterogeneity in research is not the salt formulation itself, but how the doses of norepinephrine are reported.

Most randomized trials fail to specify which formulation they used, and critically, how they calculated the dose—whether they reported the dose based on the total salt compound or the active molecular base.

To eliminate this ambiguity and improve evidence synthesis, leading critical care societies (such as the European Society of Intensive Care Medicine and the Society of Critical Care Medicine) have officially recommended that all research publications report norepinephrine doses in its base form (molecular norepinephrine), regardless of the salt used.

Read More